CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indivior PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indivior PLC
10710 Midlothian Turnpike
Suite 125, North Chesterfield
Phone: 804-3791090p:804-3791090 CHESTERFIELD, VA  23235  United States Ticker: INDVINDV
Business Summary
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
(Source: PROXY)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board GrahamHetherington 60 1/1/2023 11/1/2019
Chief Executive Officer, Executive Director MarkCrossley 6/29/2020 2/3/2017
Chief Financial Officer, Executive Director RyanPreblick 11/19/2020 6/29/2020
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Indivior Finance S.ar.l. Luxembourg
RBP Global Holdings, Ltd. 103-105 Bath Road Berkshire United Kingdom
Indivior plc United Kingdom
Opiant Pharmaceuticals Inc 233 Wilshire Blvd, Suite 400 SANTA MONICA CA United States

Business Names
Business Name
A12FHW
Bio-Found Limited
Indivior (Beijing) Pharmaceuticals Information Consulting Co. Ltd
73 additional Business Names available in full report.

General Information
Number of Employees: 1,051 (As of 12/31/2023)
Outstanding Shares: 126,526,967 (As of 11/15/2024)
Shareholders: 806
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024